Pharmacologically Dosed Oral Glutamine Reduces Myocardial Injury in Patients Undergoing Cardiac Surgery: A Randomized Pilot Feasibility Trial.

Sufit A, Weitzel LB, Hamiel C, Queensland K, Dauber I, Rooyackers O, Wischmeyer PE.
Journal   J Parenter Enteral Nutr.
Species  
Analytes Measured   HSP70 , Myoglobin , Troponin I fast-twitch
Matrix Tested   Serum
Year   2012
Volume  
Page Numbers  
Application   Cardiac
Abstract
OBJECTIVE: Glutamine (GLN) has been shown to protect against in vitro and in vivo myocardial injury. In humans, perioperative ischemia/reperfusion (I/R) injury during cardiac surgery is associated with higher morbidity and mortality. The objective of this safety and feasibility pilot trial was to determine if pharmacologically dosed, preoperative oral GLN attenuates myocardial injury in cardiac surgery patients.

METHODS: Patients undergoing elective cardiac surgery, requiring cardiopulmonary bypass, were enrolled in a randomized, double-blind pilot trial to receive 25 g twice of oral alanyl-glutamine (GLN; n = 7) or maltodextrin (CONT; n = 7) daily for 3 days preoperatively. Serum troponin (TROP I), creatine kinase (CK-MB), and myoglobin (MG) were measured at multiple perioperative time points. Clinical outcomes were also recorded and assessed.

RESULTS: GLN therapy significantly decreased TROP I levels at 24, 48, and 72 hours postoperatively (all P < .05) vs CONT. GLN also reduced CK-MB at 24 and 48 hours (P < .05, P < .001) vs CONT. MG was reduced at 24 hours vs control (P = .0397). GLN also significantly reduced pooled clinical complications vs CONT (P = .03). Conclusion: This pilot study showed that pharmacologically dosed oral GLN therapy prior to cardiac surgery was safe, well tolerated, and feasible. GLN therapy reduced myocardial injury and clinical complications in this small randomized, blinded feasibility trial. These data indicate that a larger trial of preoperative GLN therapy in patients undergoing cardiac surgery is needed to confirm clinical benefit.

View Publications

Related Products

R-PLEX Human HSP70 Antibody Set
HSP70 | Human
Singleplex
Muscle Injury Panel 3 Mouse Kit
cTroponin I, FABP3/H-FABP, Myl3/CMLC1, Troponin I (fast-twitch) | Mouse
Multiplex
Muscle Injury Panel 1 Rat Kit
cTroponin I, FABP3/H-FABP, Myl3/CMLC1, Troponin I (fast-twitch), Troponin T (cardiac) | Rat
Multiplex
Rat Skeletal Troponin I Kit
Troponin I (fast-twitch) | Rat
Singleplex
Total HSP70 Whole Cell Lysate Kit
HSP70 | Human
Singleplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters